Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IBA, NST combine in molecular imaging pact

This article was originally published in Clinica

Executive Summary

Radiopharmaceuticals company Ion Beam Applications (IBA) and Israeli firm NeuroSurvival Technologies (NST) will work together to scale up manufacturing of the latter's Aposense molecular imaging agent and make it available to multi-center clinical trial sites in the US. Aposense targets cells that are undergoing apoptosis, or programmed cell death, a phenomenon associated with many medical disorders. The two firms will first develop the radio-chemistry and processes needed for GMP-grade radio-labelling of Aposense, making it compatible for large scale commercialisation and distribution. IBA (Louvain-la-Neuve, Belgium) and NST will both supply the radio-labelled agent to the clinical trial sites and will negotiate commercial supply terms following FDA approval of the product. Financial terms of the agreement were not revealed.

You may also be interested in...

Alere aided by professional diagnostics sales in fourth quarter

Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.

Integra and Stout to work on expandable interbody device

Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.

Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials

Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts